Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Myelodysplastic Syndromes
NCT00015990Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2001
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoints: Confirmed Response (CHR, PR, HI) up to 3 months and Incidence and Severity of Toxicities up to 5 years. Started Apr 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00015990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015990.